What is the recommended protocol to initiate feminizing hormone therapy in an adult transgender woman?

How to Start Feminizing Hormone Therapy for Transgender Women

Feminizing hormone therapy for transgender women should be initiated with estrogen (oral 17β-estradiol, transdermal, or parenteral estrogen esters) combined with an antiandrogen (spironolactone or cyproterone acetate), targeting estradiol levels ≤200 pg/mL and testosterone levels <55 ng/dL in the female range. 1

Pre-Treatment Requirements

Before initiating hormones, you must:

• Confirm diagnosis and readiness: Verify that a mental health professional has diagnosed gender identity disorder/gender dysphoria and confirmed eligibility criteria 1
• Screen for contraindications: Evaluate cardiovascular risk factors, history of thromboembolic disease, liver disease, and smoking status 1
• Obtain baseline labs: Prolactin, complete blood count, liver function tests, lipids, fasting glucose, testosterone, and estradiol 1
• Counsel on fertility: Discuss fertility preservation options before starting therapy, as hormone treatment may permanently impair spermatogenesis 1

Hormone Regimen

Estrogen Options:

• Oral 17β-estradiol (preferred over conjugated estrogens)
• Transdermal estrogen (preferred in patients >40 years or with thromboembolic risk factors) 1
• Parenteral estrogen esters (intramuscular)

Critical caveat: Avoid ethinyl estradiol due to 20-fold increased risk of venous thromboembolism and inability to monitor serum levels 1

Antiandrogen Options:

• Spironolactone: Directly inhibits testosterone secretion and androgen receptor binding 1
• Cyproterone acetate: Progestational compound with antiandrogenic properties (widely used in Europe) 1
• GnRH agonists (e.g., goserelin acetate): Effective with low adverse reaction incidence 1

Do not use flutamide due to liver toxicity and unproven efficacy 1

Target Hormone Levels

• Estradiol: Maintain at mean premenopausal female levels (≤200 pg/mL) 1
• Testosterone: Suppress to female range (<55 ng/dL) 1

The Endocrine Society guidelines emphasize avoiding supraphysiological estrogen doses, which increase risks of thromboembolic disease, liver dysfunction, and hypertension 1. While some recent research questions whether the 100-200 pg/mL range is optimal 2, the established guideline remains the standard of care for safety.

Monitoring Protocol

First Year:

• Clinical visits: Every 2-3 months to assess feminization and adverse effects 1
• Labs every 2-3 months: Estradiol, testosterone, prolactin, CBC, liver function tests 1
• Cardiovascular monitoring: Blood pressure, weight, lipids, fasting glucose at each visit 1

After First Year:

• Clinical visits: 1-2 times yearly 1
• Labs: Prolactin at least annually during transition, then biannually 1
• Continue cardiovascular risk assessment 1

Expected Timeline of Feminization

Physical changes occur gradually 1:

• 1-3 months: Decreased libido, decreased spontaneous erections
• 3-6 months: Breast growth begins, body fat redistribution starts, decreased muscle mass, softer skin
• 6-12 months: Decreased terminal hair growth begins
• Maximum effects: 2-3 years for breast development and body composition changes

Important limitation: Voice does not change with hormones; scalp hair does not regrow 1

Critical Safety Considerations

Thromboembolic Risk:

The most serious complication is venous thromboembolism. Screen for personal or family history of clotting disorders before initiating therapy 1. Do not routinely screen all patients for thrombophilia—only those with positive personal or family history 1. Strongly encourage smoking cessation to reduce cardiovascular and thromboembolic complications 1.

Prolactin Monitoring:

Up to 20% of patients may develop hyperprolactinemia with pituitary enlargement 1. Most cases resolve with estrogen dose reduction. Only pursue pituitary imaging if prolactin levels persistently increase despite stable or reduced estrogen doses 1.

Liver Function:

Monitor transaminases, though serious hepatotoxicity is rare with bioidentical estrogens (unlike oral alkylated compounds) 1.

Common Pitfalls to Avoid

1. Using ethinyl estradiol: Associated with dramatically increased thrombosis risk 1
2. Supraphysiological estrogen dosing: Does not improve feminization but increases adverse events 1
3. Inadequate testosterone suppression: Limits feminizing effects; ensure antiandrogen is adequate 1
4. Skipping fertility counseling: Hormone therapy may cause irreversible infertility 1, 3
5. Inadequate cardiovascular screening: Particularly critical in patients who smoke or have diabetes 1

The evidence strongly supports that feminizing hormone therapy, when properly prescribed and monitored, is safe and effective, significantly improving quality of life and reducing gender dysphoria 4, 5, 6, 7.